CTOR Company Profile and Key Details

Citius Oncology, Inc. generated EPS of -$0.31 over the past year. Five-year average earnings growth is -309.67%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $6.00. The high target offers 710.81% upside. The low target suggests 710.81% downside. The mean target is $6.00. This offers 710.81% upside. Citius Oncology, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 14, 2026, missed forecasts by 14.29%. The prior quarter beat by 2600.0%. Over the last six quarters, Apple has recorded several small beats. These include -46.67% in August 12, 2025.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

CTOR has shown mixed momentum, losing -1.87% over the past week and -38.24% over the past quarter, though year-to-date performance is up 5.0%. Short-term trend indicators are mixed aligned (SMA20 -3.88%, SMA50 -3.19%, SMA200 -32.83%). The stock’s 14-day RSI is 43.99 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -82.39% below its high and over 97.97% above its low. Average 10-day trading volume of 97.88 thousand shares is slightly above the 3-month average of 77.22 thousand, indicating heightened recent market interest.

Citius Oncology, Inc. has 92.98 million shares outstanding. The public float is 17.72 million shares, elevated short interest at 2.17% of float. This equals 365.15 thousand shares. The short ratio is 8.47 days. Institutional investors hold 68.14% of the float. Insiders own 77.51%.

Citius Oncology, Inc. (NASDAQ:CTOR) closed at $0.74 USD, losing -$0.02 (-2.02%) from the previous close of $0.76. The stock is currently mid-range between its 52-week high and low $0.49 and $2.25. With a market capitalization of about $69.16 million, Citius Oncology, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.49). Key stats such as the average daily volume over the past year has been around 85.40 thousand shares, volume is running light vs its 52-week average. Headquartered in Cranford, NY, Citius Oncology, Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Leonard L. Mazur, the company employs approximately 285 people and listed since December 08, 2022. Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types.

Citius Oncology, Inc. trades at a P/E ratio of -1.55, slightly below the S&P 500 average, with a price-to-sales ratio of 9.67 and a price-to-book ratio of 1.97 suggesting the stock is closer to book value. The P/FCF stands at -3.49, also below market averages.

Our AI price prediction model suggests that Citius Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 19.66%, with price expected at $0.89 by September 03, 2026, within a range of $0.82 to $0.96 3-Month Outlook: Projected rise of 491.56%, reaching $4.40 by November 18, 2026, with a range of $3.20 to $4.96. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by August 20, 2027, within a range of $0.00 to $0.70.

Citius Oncology, Inc. (NASDAQ:CTOR) shares are flat 5.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Citius Oncology, Inc. trading at a premium to the broader market with a P/E of -1.55. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.50, suggesting 505.0% upside. Our AI forecast model points to short-term strength (19.66% over two weeks), a medium-term rise (491.56% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.